HUMAN IMMUNE CELL REGULATED SUPPRESSION OF HIV1
人类免疫细胞调节抑制 HIV1
基本信息
- 批准号:2887944
- 负责人:
- 金额:$ 23.7万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-09-30 至 2001-09-29
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Most HIV-I infections are initiated by M-tropic strains which
subsequently switch to predominantly T-tropic HIV infection during the
rapid progression of AIDS. A better understanding of the biological
basis of the switch from M-tropic to T-tropic HIV-infection will be
significant in our ability to contain viral infection, early in its
asymptotic state. We wish to test the hypothesis that a markedly
reduced level of viral replication will limit the switch from M-tropic
to T-tropic HIV-1 infection. We propose to block early stages, (prior
to the synthesis of viral antigens), of HIV-1 infection by exploiting
the properties of a recently discovered cellular inhibitor of HIV-1 gene
trans-activation. This is significant since currently available immune
therapies or the antiviral agents mainly target infected cells which
display viral antigens. In spite of the progress in antiviral triple
drug therapy, reservoirs of virus persist in lymph nodes that remain
unaffected by currently available drugs (2-5, 7, 8, 15). We suggest
that an endogenous inhibitor of early viral life cycle will complement
the potency of available antiviral therapy to achieve a stable cure for
AIDS. Importantly, the proposal is relevant to the goals of PA-98-040,
since the inhibitory properties of the endogenous HIV-1 suppressor,
NF90, is regulated by the mitogenic signal transduction pathways of
human primary immune cells. A better understanding of the cell cycle,
regulated control of HIV-I expression in human primary T-cells will be
important to design stable cure for AIDS. The overall goal of this
project is to build upon our preliminary studies and utilizing
immunoliposomes targeted to CCR5 expressing cells, deliver the NF90
expression constructs to assess its effectiveness as an inhibitor of
HIV-I replication in primary human lymphocytes.
大多数HIV-I感染是由嗜m型毒株引起的
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ajit Kumar其他文献
Ajit Kumar的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ajit Kumar', 18)}}的其他基金
HIV-1 Inhibition using Tat Peptide Derivatives
使用 Tat 肽衍生物抑制 HIV-1
- 批准号:
7894143 - 财政年份:2009
- 资助金额:
$ 23.7万 - 项目类别:
Induction of Interferon to Block HIV-1 Replication
诱导干扰素阻断 HIV-1 复制
- 批准号:
6591089 - 财政年份:2003
- 资助金额:
$ 23.7万 - 项目类别:
Induction of Interferon to Block HIV-1 Replication
诱导干扰素阻断 HIV-1 复制
- 批准号:
6751877 - 财政年份:2003
- 资助金额:
$ 23.7万 - 项目类别:
HIV-1 Inhibition using Tat Peptide Derivatives
使用 Tat 肽衍生物抑制 HIV-1
- 批准号:
7367875 - 财政年份:1999
- 资助金额:
$ 23.7万 - 项目类别:
HUMAN IMMUNE CELL REGULATED SUPPRESSION OF HIV1
人类免疫细胞调节抑制 HIV1
- 批准号:
2801908 - 财政年份:1998
- 资助金额:
$ 23.7万 - 项目类别:
CELL CYCLE REGULATED HOST PROTEINS IN VIRAL ACTIVATION
病毒激活中细胞周期调节的宿主蛋白
- 批准号:
2292663 - 财政年份:1997
- 资助金额:
$ 23.7万 - 项目类别:
相似海外基金
Role of novel RNA binding protein LARP6 in alcoholic cardiomyopathy
新型RNA结合蛋白LARP6在酒精性心肌病中的作用
- 批准号:
10593688 - 财政年份:2023
- 资助金额:
$ 23.7万 - 项目类别:
Targeting of RNA-binding protein FXR1 in HNSCC
HNSCC 中 RNA 结合蛋白 FXR1 的靶向
- 批准号:
10571379 - 财政年份:2023
- 资助金额:
$ 23.7万 - 项目类别:
Mechanisms driving Autosomal Dominant Polycystic Kidney Disease: The novel role of the RNA-binding protein ANKHD1.
常染色体显性多囊肾病的驱动机制:RNA 结合蛋白 ANKHD1 的新作用。
- 批准号:
MR/T04201X/2 - 财政年份:2023
- 资助金额:
$ 23.7万 - 项目类别:
Fellowship
Identify the role of RNA-binding protein in activating anti-tumor immunity by directly decaying PD-L1-3'UTR
通过直接降解 PD-L1-3UTR 鉴定 RNA 结合蛋白在激活抗肿瘤免疫中的作用
- 批准号:
23KJ1296 - 财政年份:2023
- 资助金额:
$ 23.7万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Anti-inflammatory Signaling of RNA-binding Protein, Tristetraprolin, During Myocardial Infarction
RNA 结合蛋白 Tristetraprolin 在心肌梗死期间的抗炎信号传导
- 批准号:
10644962 - 财政年份:2023
- 资助金额:
$ 23.7万 - 项目类别:
Formation and function of pathologic stress granules containing RNA-Binding Protein SFPQ in tauopathy
tau蛋白病中含有RNA结合蛋白SFPQ的病理应激颗粒的形成和功能
- 批准号:
10581946 - 财政年份:2023
- 资助金额:
$ 23.7万 - 项目类别:
Role of RNA-binding protein in immune evasion of Mtb in macrophages
RNA结合蛋白在巨噬细胞中Mtb免疫逃避中的作用
- 批准号:
10634764 - 财政年份:2022
- 资助金额:
$ 23.7万 - 项目类别:
Post-transcriptional regulation by the YBX3 RNA-binding protein in skeletal muscle
骨骼肌中 YBX3 RNA 结合蛋白的转录后调节
- 批准号:
10439013 - 财政年份:2022
- 资助金额:
$ 23.7万 - 项目类别:
ERK-mediated regulation of RNA binding protein condensation during female germ cell development
ERK 介导的雌性生殖细胞发育过程中 RNA 结合蛋白凝聚的调节
- 批准号:
10514951 - 财政年份:2022
- 资助金额:
$ 23.7万 - 项目类别:
Evolution of RNA Binding Protein Regulation of Brain Development
RNA结合蛋白对大脑发育调节的进化
- 批准号:
2735241 - 财政年份:2022
- 资助金额:
$ 23.7万 - 项目类别:
Studentship